Education
About Us
Working with TipRanks
Follow Us
Active Biotech AB (SE:ACTI)
:ACTI
RESEARCH TOOLSreports
ACTI Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.06 - kr0.52
Previous CloseN/A
Volume903.68K
Average Volume (3M)29.81M
Market Cap
kr296.47M
Enterprise Valuekr84.30M
Total Cash (Recent Filing)kr27.40M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.72
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,230,164,700
10 Day Avg. Volume59,427,262
30 Day Avg. Volume29,809,797
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Active Biotech AB News
PremiumCompany Announcements
Active Biotech’s Tasquinimod Shows Promise in Multiple Myeloma Study
PremiumCompany Announcements
Active Biotech Secures European Patent for Tasquinimod in Myelofibrosis
PremiumCompany Announcements
Active Biotech AB Announces 2025 Annual General Meeting
PremiumCompany Announcements
Active Biotech Announces 2025 AGM and Board Re-electionsPremiumCompany Announcements
Active Biotech AB Announces 2025 Annual General Meeting
PremiumCompany Announcements
Active Biotech AB Announces 2025 Annual General Meeting
PremiumCompany Announcements
Active Biotech AB Announces Annual General Meeting and Key Resolutions
PremiumCompany Announcements
Active Biotech AB Announces 2025 Annual General Meeting DetailsACTI FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was kr0.06 and its highest was kr0.52 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr296.47M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Aug 21, 2025 which is in 86 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on May 08, 2025. The company reported -kr0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.009.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 1,230,164,700 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.784%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in SE:ACTI
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Alligator Bioscience AB
―
Biosergen AB
―
Biovica International AB Class B
―
Nanologica AB
―